Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigator the Effect of P-glycoprotien Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigator the Effect of P-glycoprotien Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itraconazole (Primary) ; Rifampicin (Primary) ; Sitravatinib (Primary)
  • Indications Breast cancer; Cancer; Gastric cancer; Liposarcoma; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Pharmacokinetics
  • Sponsors Mirati Therapeutics

    • Most Recent Events

    • 14 May 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health.
    • 15 Mar 2023 Status changed from active, no longer recruiting to completed.
    • 17 Nov 2022 Planned End Date changed from 12 Oct 2022 to 30 Jan 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top